$ARDS is using monoclonal antibodies to counter se
Post# of 46489
From the company news:
*Announced the addition of a second inhaled monoclonal antibody ("mAb" to neutralize newly emerging COVID-19 mutated variant to form a cocktail of two mAbs. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering. A clinical Phase 1/2 study is expected to be launched in 2H 2021.
More Info here: http://www.prnewswire.com/news-releases/aridi...89072.html